Cargando…

F225. LEVODOPA AUGMENTATION OF ANTIPSYCHOTICS FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

BACKGROUND: Negative symptoms (i.e., motivation deficits and diminished emotional expression) are prevalent in schizophrenia and consistently linked with functional impairment for affected individuals. Despite advances in psychopharmacology for schizophrenia, there remain no effective treatments for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foussias, George, Rao, Naren, Fervaha, Gagan, Borlido, Carol, Haber, Lillian, Takeuchi, Hiroyoshi, Mizrahi, Romina, Remington, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887820/ http://dx.doi.org/10.1093/schbul/sby017.756

Ejemplares similares

F121. DOES RELAPSE CONTRIBUTE TO TREATMENT RESISTANCE? ANTIPSYCHOTIC RESPONSE IN FIRST- VS. SECOND-EPISODE SCHIZOPHRENIA
por: Takeuchi, Hiroyoshi, et al.
Publicado: (2018)

Treating Negative Symptoms in Schizophrenia: an Update
por: Remington, Gary, et al.
Publicado: (2016)

S76. A BEHAVIOURAL ECONOMIC ANALYSIS OF EFFORT-RELATED CHOICE IN SCHIZOPHRENIA
por: Fervaha, Gagan, et al.
Publicado: (2018)

F219. NOVEL OBJECTIVE ASSESSMENT OF ACTIVITY ENGAGEMENT IN SCHIZOPHRENIA USING WIRELESS MOTION CAPTURE
por: Siddiqui, Ishraq, et al.
Publicado: (2018)

S225. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OR PREVENTION OF WEIGHT GAIN IN SCHIZOPHRENIA
por: Agarwal, Sri Mahavir, et al.
Publicado: (2018)

Interpreting a Multivariate Analysis of Functional Neuroimaging Data
por: Fervaha, Gagan, et al.
Publicado: (2012)

Peripheral Amino Acid Levels in Schizophrenia and Antipsychotic Treatment
por: De Luca, Vincenzo, et al.
Publicado: (2008)

Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D(2/3) Receptors in the Ventral Striatum of Healthy Nonobese Humans
por: Caravaggio, Fernando, et al.
Publicado: (2015)

Entorhinal Cortex Volume in Antipsychotic-naïve Schizophrenia
por: Jose, Sam P., et al.
Publicado: (2012)

T232. EFFICACY AND SAFETY OF ANTIDEPRESSANT AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA
por: Galling, Britta, et al.
Publicado: (2018)

The Role of Leptin in Antipsychotic-Induced Weight Gain: Genetic and Non-Genetic Factors
por: Panariello, Fabio, et al.
Publicado: (2012)

T225. OPERATIONAL DEFINITIONS FOR ANTIPSYCHOTIC RESPONSE IN DELUSIONAL DISORDER: A SYSTEMATIC AND CRITICAL REVIEW
por: González-Rodríguez, Alexandre, et al.
Publicado: (2018)

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018)

S175. AMOTIVATION IS ASSOCIATED WITH SMALLER VENTRAL STRIATUM VOLUMES IN OLDER PATIENTS WITH SCHIZOPHRENIA
por: Caravaggio, Fernando, et al.
Publicado: (2018)

O1.5. CLUSTERING-BASED BEHAVIOURAL PHENOTYPES OF INTRINSIC MOTIVATION IN SCHIZOPHRENIA DETERMINED USING OBJECTIVELY QUANTIFIED REAL-WORLD PERFORMANCE
por: Siddiqui, Ishraq, et al.
Publicado: (2020)

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

A Longitudinal Study of Relation between Side-effects and Clinical Improvement in Schizophrenia: Is There a Neuro-metabolic Threshold for Second Generation Antipsychotics?
por: Venkatasubramanian, Ganesan, et al.
Publicado: (2013)

S119. A DIMENSIONAL APPROACH TO UNDERSTANDING COST-BENEFIT DECISION-MAKING IN SCHIZOPHRENIA AND DEPRESSION
por: Saperia, Sarah, et al.
Publicado: (2020)

Behavioural phenotypes of intrinsic motivation in schizophrenia determined by cluster analysis of objectively quantified real-world performance
por: Siddiqui, Ishraq, et al.
Publicado: (2022)

Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
por: Singh, Raghunath, et al.
Publicado: (2022)

Inferior Parietal Lobule Volume and Schneiderian First-Rank Symptoms in Antipsychotic-Naïve Schizophrenia: A 3-Tesla MRI Study
por: Danivas, Vijay, et al.
Publicado: (2009)

Augmentation of Antipsychotic Medications with Low-Dose Clozapine in Treatment-Resistant Schizophrenia—Case Reports and Discussion
por: Harrison, Zoe, et al.
Publicado: (2021)

Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2016)

Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia
por: Itahashi, Takashi, et al.
Publicado: (2021)

Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis
por: Kanagasundaram, Pruntha, et al.
Publicado: (2021)

Development and acceptability testing of a decision aid for considering whether to reduce antipsychotics in individuals with stable schizophrenia
por: Aoki, Yumi, et al.
Publicado: (2023)

Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan
por: Hatano, Masakazu, et al.
Publicado: (2021)

Successful Use of Add - On Topiramate for Antipsychotic - Induced Weight Gain
por: Shivakumar, Venkataram, et al.
Publicado: (2012)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Simulating real world functioning in schizophrenia using a naturalistic city environment and single-trial, goal-directed navigation
por: Zawadzki, John A., et al.
Publicado: (2013)

ACCIDENTA C-225
por: Departments, HR
Publicado: (2010)

Synthesis and Stability of Actinium-225 Endohedral Fullerenes, (225)Ac@C(60)
por: Mwakisege, Jofa Gideon, et al.
Publicado: (2020)

Mortality in Levodopa-Treated Parkinson's Disease
por: Morgan, John C., et al.
Publicado: (2014)

Atypical Antipsychotics as Augmentation Therapy in Anorexia Nervosa
por: Marzola, Enrica, et al.
Publicado: (2015)

Antipsychotic augmentation in the treatment of obsessive-compulsive disorder
por: Thamby, Abel, et al.
Publicado: (2019)

Mortality risk of antipsychotic augmentation for adult depression
por: Gerhard, Tobias, et al.
Publicado: (2020)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Comparative effectiveness of antipsychotic drugs in schizophrenia
por: Stroup, T. Scott, et al.
Publicado: (2000)

The heterogeneity of antipsychotic response in the treatment of schizophrenia
por: Case, M., et al.
Publicado: (2011)

New atypical antipsychotics for schizophrenia: iloperidone
por: Caccia, Silvio, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_3bpsccjqh1k2ajjeas0ec4vn96